Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC)

Authors :: J. Carmichael
Craig P. Carden
S. B. Kaye
D. S. Tan
J.S. de Bono
J. Hanwell
J.E. Ang
M. E. Gore
T. A. Yap
Peter C.C. Fong
Source :: Journal of Clinical Oncology. 28:5041-5041
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: 5041 Background: A synthetic lethal approach by PARP inhibition has clinical activity in BDOC (NEJM 2009; 361: 123-34). Proposed mechanisms of PARPi resistance include the restoration of BRCA1/2 fu...

Subjects :: Cancer Research
Chemotherapy
Pathology
medicine.medical_specialty
business.industry
Poly ADP ribose polymerase
medicine.medical_treatment
medicine.disease
Poly (ADP-Ribose) Polymerase Inhibitor
Olaparib
chemistry.chemical_compound
Oncology
chemistry
Cancer research
medicine
In patient
Ovarian cancer
business

Full Text Access

Tools